What Verdica's 799 score means for ALKERMES INC
ALKERMES INC scores 799 out of 850 on Verdica's composite scale, placing it in the "strong" band (740–799). This score reflects consistent compliance across regulated pharmacy operations, with no major red flags in the underlying data from state boards, FDA records, or DEA filings.
A score in this range signals that the provider meets or exceeds baseline regulatory requirements and demonstrates a track record of operational diligence. It does not mean the entity is perfect—no pharmacy provider scores 850—but it does indicate that a business or consumer evaluating this provider is unlikely to encounter compliance-related disruptions or enforcement actions based on historical patterns.
Readers should interpret this score as a proxy for regulatory reliability. When state pharmacy boards, the FDA, and DEA monitor a provider, they flag issues like license lapses, product recalls, manufacturing defects, or controlled substance discrepancies. A strong score suggests those flags are absent or minimal. This matters because compliance lapses can ripple into operational delays, product shortages, or legal exposure for partners and customers.
Note that no independent customer reviews are indexed for ALKERMES INC on Verdica yet, so this score is built entirely on regulator-sourced data. That limits the picture to compliance posture, not customer experience, pricing, or service quality.
How the sub-scores break down
Product Approval (850 / 850): This sub-score is maxed out. It reflects the FDA's track record of approving ALKERMES INC's products for market distribution. A perfect score here means the entity has cleared FDA review processes without rejections, withdrawals, or conditional approvals requiring remediation. In the pharmacy industry, this is the baseline expectation, but maintaining it consistently across multiple product lines or formulations is operationally significant.
Manufacturer Profile (720 / 850): This is the weakest of the three sub-scores, though still within acceptable range. This dimension typically captures state board licensing data, facility inspections, and operational certifications. A score of 720 suggests ALKERMES INC holds all required licenses and registrations, but may have historical notes—minor violations, conditional renewals, or inspection findings—that regulators have logged. These are not disqualifying, but they indicate the regulator flagged something worth monitoring. Common examples include staffing documentation gaps, labeling inconsistencies, or supply chain record-keeping issues.
FDA Compliance (830 / 850): This strong sub-score reflects FDA inspection outcomes, adverse event reporting, and manufacturing standard adherence. A score of 830 indicates ALKERMES INC has passed recent FDA reviews with minimal observations. FDA inspectors often issue "Form 483" observations (minor non-compliance notes) rather than formal warnings; a score this high suggests any such notes were resolved quickly.
What regulators track for pharmacy providers
State pharmacy boards oversee licensure, facility standards, pharmacist oversight, and inventory controls. They conduct inspections and log violations ranging from minor (paperwork delays) to serious (unauthorized practice, theft, or adulteration).
The FDA monitors manufacturing, product quality, labeling accuracy, and adverse event reporting. They inspect facilities on a risk-based schedule and issue warning letters or consent decrees for systemic failures like contamination, mislabeling, or false claims.
The DEA tracks controlled substance handling, record-keeping, and diversion risk. Pharmacy providers that dispense or manufacture Schedule II–V drugs must maintain precise logs, physical security, and audit trails. DEA inspections focus on whether inventory reconciles and whether prescriptions follow legal protocols.
Scores move up when providers maintain clean inspection histories and respond promptly to regulator requests. They move down when boards issue non-renewal notices, FDA identifies manufacturing defects, or DEA discovers discrepancies in controlled substance accounting.
Bottom line
ALKERMES INC presents a strong compliance profile based on regulator data, with no material red flags. A business partner or consumer should still cross-check current licensing status directly with state boards and review any specific product lines of concern, but the historical record indexed by Verdica supports confidence in regulatory adherence.